Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocardial Infarction | 12 | 2024 | 466 | 3.330 |
Why?
|
| Acute Coronary Syndrome | 7 | 2024 | 167 | 3.070 |
Why?
|
| Chest Pain | 12 | 2024 | 205 | 1.570 |
Why?
|
| Troponin T | 7 | 2024 | 92 | 1.410 |
Why?
|
| Cardiology | 5 | 2024 | 104 | 1.350 |
Why?
|
| Troponin | 8 | 2024 | 101 | 1.260 |
Why?
|
| Emergency Medical Services | 5 | 2023 | 183 | 1.180 |
Why?
|
| Early Detection of Cancer | 2 | 2023 | 100 | 0.860 |
Why?
|
| Adult | 30 | 2024 | 9259 | 0.830 |
Why?
|
| Mortality | 2 | 2020 | 122 | 0.760 |
Why?
|
| Prospective Studies | 15 | 2024 | 2316 | 0.750 |
Why?
|
| Emergency Service, Hospital | 11 | 2024 | 444 | 0.730 |
Why?
|
| Humans | 54 | 2024 | 32282 | 0.730 |
Why?
|
| Nursing Staff | 1 | 2022 | 7 | 0.720 |
Why?
|
| Middle Aged | 34 | 2024 | 11851 | 0.710 |
Why?
|
| Hospitalization | 3 | 2023 | 475 | 0.700 |
Why?
|
| Genital Neoplasms, Female | 6 | 2017 | 29 | 0.690 |
Why?
|
| Colorectal Neoplasms | 1 | 2023 | 219 | 0.660 |
Why?
|
| Predictive Value of Tests | 7 | 2024 | 883 | 0.660 |
Why?
|
| Hypercholesterolemia | 3 | 2023 | 73 | 0.560 |
Why?
|
| Ethnic Groups | 1 | 2020 | 450 | 0.550 |
Why?
|
| Female | 34 | 2024 | 19945 | 0.550 |
Why?
|
| Head and Neck Neoplasms | 5 | 2022 | 137 | 0.510 |
Why?
|
| Deglutition Disorders | 2 | 2014 | 53 | 0.490 |
Why?
|
| Male | 26 | 2024 | 19441 | 0.480 |
Why?
|
| Mass Screening | 3 | 2023 | 256 | 0.470 |
Why?
|
| Aged | 23 | 2024 | 10263 | 0.450 |
Why?
|
| Models, Statistical | 1 | 2014 | 187 | 0.390 |
Why?
|
| Neoplasms | 4 | 2024 | 754 | 0.370 |
Why?
|
| Gynecologic Surgical Procedures | 3 | 2017 | 47 | 0.350 |
Why?
|
| Treatment Outcome | 7 | 2017 | 3416 | 0.340 |
Why?
|
| Death | 4 | 2024 | 51 | 0.330 |
Why?
|
| Algorithms | 5 | 2024 | 536 | 0.330 |
Why?
|
| Coronary Artery Disease | 2 | 2024 | 427 | 0.310 |
Why?
|
| North Carolina | 7 | 2023 | 1300 | 0.290 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2018 | 11 | 0.280 |
Why?
|
| Cohort Studies | 10 | 2024 | 1840 | 0.270 |
Why?
|
| Atherosclerosis | 2 | 2023 | 820 | 0.250 |
Why?
|
| Caregivers | 3 | 2024 | 114 | 0.250 |
Why?
|
| Quality of Life | 6 | 2022 | 964 | 0.250 |
Why?
|
| Postoperative Complications | 3 | 2017 | 823 | 0.250 |
Why?
|
| Decision Making | 2 | 2022 | 189 | 0.240 |
Why?
|
| Young Adult | 11 | 2024 | 2649 | 0.240 |
Why?
|
| Tamoxifen | 2 | 2017 | 59 | 0.240 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 443 | 0.230 |
Why?
|
| Odds Ratio | 4 | 2020 | 456 | 0.230 |
Why?
|
| Cardiovascular Diseases | 3 | 2022 | 1158 | 0.230 |
Why?
|
| Logistic Models | 4 | 2020 | 743 | 0.220 |
Why?
|
| Retrospective Studies | 11 | 2023 | 3626 | 0.210 |
Why?
|
| United States | 5 | 2024 | 4072 | 0.210 |
Why?
|
| Consensus | 1 | 2024 | 87 | 0.200 |
Why?
|
| Rural Population | 2 | 2023 | 216 | 0.200 |
Why?
|
| Government Programs | 1 | 2023 | 11 | 0.200 |
Why?
|
| Adolescent | 9 | 2023 | 3519 | 0.200 |
Why?
|
| Colonoscopy | 1 | 2023 | 45 | 0.190 |
Why?
|
| Primary Health Care | 2 | 2022 | 232 | 0.190 |
Why?
|
| Risk Factors | 8 | 2024 | 3934 | 0.190 |
Why?
|
| Hyperlipidemias | 1 | 2023 | 61 | 0.190 |
Why?
|
| Risk Assessment | 7 | 2024 | 1425 | 0.190 |
Why?
|
| Tablets | 1 | 2022 | 10 | 0.180 |
Why?
|
| Olfaction Disorders | 1 | 2021 | 7 | 0.180 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2021 | 34 | 0.170 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2014 | 157 | 0.170 |
Why?
|
| Cross Infection | 1 | 2021 | 57 | 0.170 |
Why?
|
| Bacteremia | 1 | 2021 | 66 | 0.170 |
Why?
|
| Coronary Disease | 1 | 2022 | 226 | 0.170 |
Why?
|
| Staphylococcal Infections | 1 | 2021 | 79 | 0.170 |
Why?
|
| Time Factors | 6 | 2024 | 2205 | 0.160 |
Why?
|
| Smoking Cessation | 1 | 2023 | 211 | 0.160 |
Why?
|
| Testicular Neoplasms | 1 | 2020 | 14 | 0.160 |
Why?
|
| Teratoma | 1 | 2020 | 9 | 0.160 |
Why?
|
| Ambulances | 1 | 2020 | 11 | 0.160 |
Why?
|
| Transportation of Patients | 1 | 2020 | 22 | 0.150 |
Why?
|
| Naloxone | 1 | 2020 | 32 | 0.150 |
Why?
|
| Narcotic Antagonists | 1 | 2020 | 47 | 0.150 |
Why?
|
| Preventive Health Services | 1 | 2020 | 39 | 0.150 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 757 | 0.150 |
Why?
|
| Medical Oncology | 2 | 2018 | 90 | 0.150 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 130 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 180 | 0.150 |
Why?
|
| Lymph Nodes | 1 | 2020 | 113 | 0.150 |
Why?
|
| Cross-Sectional Studies | 5 | 2023 | 1479 | 0.150 |
Why?
|
| Sex Factors | 1 | 2020 | 655 | 0.140 |
Why?
|
| Neoplasms, Second Primary | 1 | 2018 | 24 | 0.140 |
Why?
|
| Electronic Health Records | 1 | 2020 | 179 | 0.140 |
Why?
|
| Patient Satisfaction | 2 | 2016 | 231 | 0.130 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 252 | 0.130 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2017 | 2 | 0.130 |
Why?
|
| Estrogen Antagonists | 1 | 2017 | 16 | 0.130 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2017 | 7 | 0.130 |
Why?
|
| European Continental Ancestry Group | 1 | 2020 | 1076 | 0.120 |
Why?
|
| Uterine Neoplasms | 1 | 2017 | 26 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 23 | 0.120 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 24 | 0.120 |
Why?
|
| Esophagectomy | 1 | 2015 | 15 | 0.120 |
Why?
|
| Esophagogastric Junction | 1 | 2015 | 10 | 0.120 |
Why?
|
| Hispanic Americans | 1 | 2020 | 772 | 0.120 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2015 | 1 | 0.120 |
Why?
|
| Esophageal Neoplasms | 1 | 2015 | 39 | 0.110 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2015 | 40 | 0.110 |
Why?
|
| Gastrectomy | 1 | 2015 | 70 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 258 | 0.110 |
Why?
|
| Upper Extremity Deep Vein Thrombosis | 1 | 2015 | 7 | 0.110 |
Why?
|
| Alleles | 1 | 2015 | 250 | 0.110 |
Why?
|
| Anxiety | 1 | 2016 | 190 | 0.110 |
Why?
|
| Stem Cell Transplantation | 1 | 2016 | 221 | 0.110 |
Why?
|
| Catheterization, Central Venous | 1 | 2015 | 62 | 0.110 |
Why?
|
| Preoperative Period | 1 | 2014 | 30 | 0.100 |
Why?
|
| Stomach Neoplasms | 1 | 2015 | 113 | 0.100 |
Why?
|
| Lymphoma | 1 | 2014 | 37 | 0.100 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2014 | 34 | 0.100 |
Why?
|
| African Americans | 1 | 2020 | 1335 | 0.100 |
Why?
|
| Health Services | 1 | 2014 | 40 | 0.100 |
Why?
|
| Aged, 80 and over | 6 | 2017 | 3900 | 0.100 |
Why?
|
| Religion and Medicine | 1 | 2013 | 18 | 0.100 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2013 | 14 | 0.100 |
Why?
|
| Esophageal Stenosis | 1 | 2013 | 6 | 0.100 |
Why?
|
| Dilatation | 1 | 2013 | 8 | 0.100 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2013 | 23 | 0.100 |
Why?
|
| Esophagoscopy | 1 | 2013 | 17 | 0.100 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 2240 | 0.100 |
Why?
|
| Computer Simulation | 1 | 2014 | 251 | 0.100 |
Why?
|
| Cell Separation | 1 | 2013 | 89 | 0.100 |
Why?
|
| Papillomavirus Vaccines | 1 | 2013 | 43 | 0.100 |
Why?
|
| Survivors | 1 | 2014 | 173 | 0.090 |
Why?
|
| Attitude to Health | 1 | 2013 | 138 | 0.090 |
Why?
|
| Parents | 1 | 2013 | 151 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 1 | 2013 | 131 | 0.090 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2013 | 158 | 0.090 |
Why?
|
| Deglutition | 1 | 2011 | 30 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 1 | 2011 | 63 | 0.090 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 762 | 0.080 |
Why?
|
| Acute Disease | 2 | 2021 | 253 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 651 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 556 | 0.070 |
Why?
|
| Obesity | 1 | 2014 | 1111 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 773 | 0.060 |
Why?
|
| Postoperative Period | 2 | 2016 | 95 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 757 | 0.050 |
Why?
|
| Prognosis | 2 | 2020 | 1534 | 0.050 |
Why?
|
| Workplace | 1 | 2023 | 37 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2024 | 153 | 0.050 |
Why?
|
| Phenotype | 2 | 2015 | 622 | 0.050 |
Why?
|
| Coronary Angiography | 1 | 2023 | 159 | 0.050 |
Why?
|
| Health Education | 1 | 2023 | 149 | 0.050 |
Why?
|
| Lipoprotein(a) | 1 | 2022 | 25 | 0.050 |
Why?
|
| Cholesterol | 1 | 2023 | 262 | 0.050 |
Why?
|
| Heart | 1 | 2023 | 177 | 0.050 |
Why?
|
| Lipids | 1 | 2023 | 253 | 0.040 |
Why?
|
| Lactoferrin | 1 | 2021 | 3 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2022 | 170 | 0.040 |
Why?
|
| Taste Disorders | 1 | 2021 | 5 | 0.040 |
Why?
|
| Infection Control | 1 | 2021 | 26 | 0.040 |
Why?
|
| Taste | 1 | 2021 | 17 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2023 | 388 | 0.040 |
Why?
|
| Focus Groups | 1 | 2022 | 123 | 0.040 |
Why?
|
| Child | 2 | 2020 | 2435 | 0.040 |
Why?
|
| Health Promotion | 1 | 2023 | 242 | 0.040 |
Why?
|
| Smell | 1 | 2021 | 45 | 0.040 |
Why?
|
| Age Factors | 1 | 2024 | 1179 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2022 | 308 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2022 | 179 | 0.040 |
Why?
|
| Point-of-Care Systems | 1 | 2020 | 44 | 0.040 |
Why?
|
| Orchiectomy | 1 | 2020 | 14 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2021 | 188 | 0.040 |
Why?
|
| Bleomycin | 1 | 2020 | 12 | 0.040 |
Why?
|
| Retroperitoneal Space | 1 | 2020 | 20 | 0.040 |
Why?
|
| Life Support Care | 1 | 2020 | 14 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2022 | 553 | 0.040 |
Why?
|
| Etoposide | 1 | 2020 | 38 | 0.040 |
Why?
|
| Eligibility Determination | 1 | 2020 | 18 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2020 | 62 | 0.040 |
Why?
|
| Cisplatin | 1 | 2020 | 78 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2020 | 168 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2020 | 94 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 222 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 504 | 0.040 |
Why?
|
| Medicare | 1 | 2020 | 219 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2023 | 1224 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2020 | 666 | 0.030 |
Why?
|
| Infant | 1 | 2020 | 1010 | 0.030 |
Why?
|
| Women's Health Services | 1 | 2016 | 10 | 0.030 |
Why?
|
| Immunologic Memory | 1 | 2016 | 33 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2016 | 120 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2020 | 1233 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 324 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2017 | 148 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 423 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2020 | 623 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 315 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 381 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 146 | 0.030 |
Why?
|
| Registries | 1 | 2016 | 294 | 0.030 |
Why?
|
| Attitude | 1 | 2014 | 37 | 0.030 |
Why?
|
| Health Status | 1 | 2016 | 355 | 0.030 |
Why?
|
| Patient Preference | 1 | 2014 | 48 | 0.030 |
Why?
|
| Genotype | 1 | 2015 | 702 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2014 | 55 | 0.030 |
Why?
|
| Continuity of Patient Care | 1 | 2014 | 73 | 0.020 |
Why?
|
| Survival Rate | 1 | 2015 | 893 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2013 | 164 | 0.020 |
Why?
|
| Linear Models | 1 | 2014 | 425 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2014 | 135 | 0.020 |
Why?
|
| Depression | 1 | 2016 | 420 | 0.020 |
Why?
|
| Internet | 1 | 2014 | 202 | 0.020 |
Why?
|
| Neck Dissection | 1 | 2011 | 11 | 0.020 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2011 | 7 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 1241 | 0.020 |
Why?
|
| Gastrostomy | 1 | 2011 | 17 | 0.020 |
Why?
|
| Laryngeal Neoplasms | 1 | 2011 | 16 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2011 | 86 | 0.020 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2011 | 23 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2011 | 187 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2011 | 239 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 555 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 853 | 0.020 |
Why?
|